Anthony J. Doyle
2020
In 2020, Anthony J. Doyle earned a total compensation of $4.1M as Chief Financial Officer at BioCryst Pharmaceuticals.
Compensation breakdown
| Bonus | $50,000 |
|---|---|
| Non-Equity Incentive Plan | $240,000 |
| Option Awards | $3,468,225 |
| Salary | $345,455 |
| Other | $14,250 |
| Total | $4,117,930 |
Doyle received $3.5M in option awards, accounting for 84% of the total pay in 2020.
Doyle also received $50K in bonus, $240K in non-equity incentive plan, $345.5K in salary and $14.3K in other compensation.
Rankings
In 2020, Anthony J. Doyle's compensation ranked 2,761st out of 13,090 executives tracked by ExecPay. In other words, Doyle earned more than 78.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,761 out of 13,090 | 79th |
Division Manufacturing | 1,056 out of 5,621 | 81st |
Major group Chemicals And Allied Products | 393 out of 2,254 | 83rd |
Industry group Drugs | 339 out of 1,954 | 83rd |
Industry Biological Products, Except Diagnostic Substances | 91 out of 411 | 78th |
Source: SEC filing on April 25, 2022.
Doyle's colleagues
We found four more compensation records of executives who worked with Anthony J. Doyle at BioCryst Pharmaceuticals in 2020.